3-苯基-7-色满醇 | 81715-96-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 中文名称: 3-苯基-7-色满醇
• 中文别名: 2H-1-苯并吡喃-7-醇,3,4-二氢-3-苯基-
• 英文名称: 3-phenylchroman-7-ol
• 英文别名: 3-phenyl-3,4-dihydro-2H-chromen-7-ol
• CAS: 81715-96-0
• 化学式: C₁₅H₁₄O₂
• 分子量: 226.275
• InChiKey: LKMWTIGVJAWQHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ORM-10103 、 3-苯基-7-色满醇 生成 5-nitro-2-(3-phenylchroman-7-yloxy)pyridine
  参考文献：
  名称：

  Compounds, which are potent inhibitors of Na+ /Ca2+ exchange mechanism and are useful in the treatment of arrhythmias

  摘要：

  式(I)中所示的治疗活性化合物：其中在式(I)中所示的变量在本文中有定义；以及其药学上可接受的盐和酯。这些化合物是钠/钙交换机制的强效抑制剂。

  公开号：

  US07425568B2
• 作为产物：
  描述：

  4-苯甲氧基-2-羟基苯甲醛 在 三乙基硅烷 、 三氟化硼乙醚 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 20.0 ℃ 、1.01 MPa 条件下， 反应 69.5h， 生成 3-苯基-7-色满醇
  参考文献：
  名称：

  2-Morpholinoisoflav-3-enes作为苯氧二酚，异苯氧二酚，雌马酚和类似物的合成中的柔性中间体：血管舒张性质，雌激素受体结合和Rho / RhoA激酶途径抑制

  摘要：

  食用异黄酮与心血管疾病的发生率降低相关。流行病学研究和临床数据提供了证据，证明异黄酮代谢物（例如异黄酮雌马酚）有助于这些有益作用。在这项研究中，我们开发了一种新的途径，可通过由苯乙醛，水杨醛和吗啉的缩合反应得到的2-吗啉代异黄酮来制取异黄酮和异黄酮。我们报告了异黄酮雌马酚和脱氧类似物的合成，以及异黄酮7,4'-二羟基异黄酮3-烯（苯氧二酚，haganin E）和7,4'-二羟基异黄酮2-烯（异苯氧二酚）。血管药理学研究表明，所有氧化的异黄酮和异黄酮都可以减弱苯肾上腺素引起的血管收缩，这不受雌激素受体拮抗剂ICI 182,780的影响。此外，2类似物）诱导内皮剥除的大鼠主动脉血管收缩，并减少GTP RhoA的形成，对雌马酚和苯氧二酚的影响最大。对大鼠子宫细胞溶质雌激素受体的配体置换研究表明，该化合物通常是弱结合剂。这些数据与至少部分地通过抑制RhoA / Rho激酶途径而产生的雌马酚和苯氧二

  DOI：

  10.1016/j.bmc.2012.02.008

文献信息

• 7-Substituted benzopyranes and process for the preparation thereof
  申请人：Chinoin Gyogyszer es Vegyeszeti Termekek Gyara R.T.

  公开号：US04391821A1

  公开（公告）日：1983-07-05

  The present invention relates to novel 7-substituted benzopyranes of formula (I), wherein R.sub.1 and R.sub.2 are hydrogen, alkyl of from 1 to 6 carbon atoms, hydroxyalkyl, alkenyl, cycloalkyl, phenylalkyl, dimethoxy-phenylalkyl, or R.sub.1 and R.sub.2 together with the joining nitrogen atom may represent a 5-7-membered heterocyclic ring, R.sub.3 is hydrogen, alkyl of from 1 to 4 carbon atoms or phenyl, R.sub.4 is hydrogen, R.sub.5 is hydrogen or phenyl, or R.sub.4 and R.sub.5 together may represent a bonding electron pair between the second and the third carbon atoms of the benzopyrane ring, R.sub.6 and R.sub.7 are hydrogen or they may represent an oxygen atom together, n is 1 or 2, with the proviso, that the pyrane ring may bear only one alkyl or phenyl substituent, and preparation process thereof. The novel compounds have valuable therapeutical effects, mainly in cardiotherapy.

  本发明涉及新型7-取代苯并吡喃母核化合物，其化学式为(I)，其中R.sub.1和R.sub.2是氢，碳原子数为1至6的烷基，羟烷基，烯丙基，环烷基，苯甲基，二甲氧基苯甲基，或者R.sub.1和R.sub.2与连接的氮原子一起可以表示一个5-7成员的杂环，R.sub.3是氢，碳原子数为1至4的烷基或苯基，R.sub.4是氢，R.sub.5是氢或苯基，或者R.sub.4和R.sub.5一起可以表示苯并吡喃环的第二和第三碳原子之间的一个键合电子对，R.sub.6和R.sub.7是氢，或者它们可以一起表示一个氧原子，n是1或2，前提是吡喃环只能带有一个烷基或苯基取代基，以及其制备过程。这些新型化合物具有宝贵的治疗作用，主要在心脏治疗方面。
• [EN] PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM<br/>[FR] DERIVES PYRIDINE SERVANT A INHIBER LE SYSTEME D'ECHANGE SODIUM/CALCIUM
  申请人：ORION CORP

  公开号：WO2004063191A1

  公开（公告）日：2004-07-29

  Therapeutically active compounds of formula (I) or (II) wherein X is -O-, -CH2- or -C(O)-; Z is -CHR12- or a valence bond; Y is -CH2-, -C(O)-, CH(OR13)-, -O-, -S-; provided that in case Z is a valence bond, Y is not C(O); the dashed line representing an optional double bond in which case Z is -CR12- ­and Y is -CH2-, -C(O)- or -CH(OR10)- (in formula II) or -CH- (in formula I); R2 and R3 are independently H, lower alkyl, lower alkoxy, -NO2, halogen, -CF3, -OH, benzyloxy or a group of formula (IIIa). R1 is H, CN, halogen, -CONH2, -COOR15, CH2NR15R18, NHC(O)R5, NHCH2R5, NHR20, NR21R22, NHC(NH)NHCH3 or, in case the compound is of formula (II) wherein the optional double bond exists or in case R2 or R3 is benzyloxy or a group of formula (IIIa) or in case the pyridine ring of formula (I) or (II) is attached to the oxygen atom in 3-, 4- or 5-position, R1 can also be -NO2 or NR16R17; R4 is H, -NO2, CN, halogen, -CONH2, -COOR15, -CH2NR15R18, -NR16R17, NHC(O)R5 or -NHC(NH)NHCH3; R5 is alkyl substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxy, or carboxyalkyl, in which the alkyl portion is optionally substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxyl, -CHR6NR,R8 or one of the following groups: formula (IVa), (IVb), (IVc), (IVd), (IVe), and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na+/Ca2+ exchange mechanism.

  式（I）或（II）的治疗活性化合物，其中X为-O-，-CH2-或-C（O）-；Z为-CHR12-或一个价键；Y为-CH2-，-C（O）-，CH（OR13）-，-O-，-S-；条件是如果Z为一个价键，则Y不是C（O）；虚线表示可选的双键，此时Z为-CR12-，Y为-CH2-，-C（O）-或-CH（OR10）-（在式（II）中）或-CH-（在式（I）中）；R2和R3独立地为H，较低的烷基，较低的烷氧基，-NO2，卤素，-CF3，-OH，苄氧基或式（IIIa）的基团。R1为H，CN，卤素，-CONH2，-COOR15，CH2NR15R18，NHC（O）R5，NHCH2R5，NHR20，NR21R22，NHC（NH）NHCH3的基团，或者，如果化合物为式（II），其中存在可选的双键，或者如果R2或R3为苄氧基或式（IIIa）的基团，或者如果式（I）或（II）的吡啶环附着在3-，4-或5-位置的氧原子上，则R1也可以是-NO2或NR16R17；R4为H，-NO2，CN，卤素，-CONH2，-COOR15，-CH2NR15R18，-NR16R17，NHC（O）R5或-NHC（NH）NHCH3；R5为烷基，其上取代有1-3个取自卤素、氨基和羟基或羧基的取代基，其中烷基部分可选地取代有1-3个取自卤素、氨基和羟基的取代基，-CHR6NR,R8或以下所示的一个基团之一：式（IVa），（IVb），（IVc），（IVd），（IVe），以及其药用可接受的盐和酯。这些化合物是Na+/Ca2+交换机制的有效抑制剂。
• Development of 3-alkyl-6-methoxy-7-hydroxy-chromones (AMHCs) from natural isoflavones, a new class of fluorescent scaffolds for biological imaging
  作者：Jianzhuang Miao、Huaqing Cui、Jing Jin、Fangfang Lai、Hui Wen、Xiang Zhang、Gian Filippo Ruda、Xiaoguang Chen、Dali Yin

  DOI：10.1039/c4cc06762b

  日期：——

  A new class of fluorophores 3-alkyl-6-methoxy-7-hydroxy-chromones (AMHCs) is developed and is suitable as reagents for biological imaging.

  一种新型荧光物质3-烷基-6-甲氧基-7-羟基-香豆素（AMHCs）已开发，并适用于生物成像试剂。
• Synthesis of Various Kinds of Isoflavones, Isoflavanes, and Biphenyl-Ketones and Their 1,1-Diphenyl-2-picrylhydrazyl Radical-Scavenging Activities
  作者：Hideyuki Goto、Yoshiyasu Terao、Shuji Akai

  DOI：10.1248/cpb.57.346

  日期：——

  Forty-eight kinds of isoflavones (8), thirty-one isoflavanes (9), and forty-seven biphenyl-ketones (10, 10′) were synthesized from eleven kinds of substituted phenols (11) and six phenylacetic acids (12). Among them, seventy-five compounds are new. The radical scavenging activities of these compounds were evaluated using 1,1-diphenyl-2-picrylhydrazyl (DPPH) at pH 6.0. We found that thirty-nine out of forty-three compounds having a catechol moiety on either the A- or the B-ring exhibited a high activity (ED50=12—54 μM) similar to that of catechin. In these cases, the remaining part of their structure seemed to have little effect on their activity. Many 6- or 8-hydroxyisoflavanes (9E—I) and their biphenyl-ketone derivatives (10E—H) also showed a high activity (ED50=<50 μM), while all of their corresponding isoflavones (8E—I) were not active at all. The 7-hydroxyisoflavanes having either an additional hydroxyl group at the C5-position (9D) or a methoxy group at the C6-position (9J) presented a high activity (ED50=26—32 μM). This study suggests that natural isoflavones have the possibilities of exhibiting antioxidant activities through the hydroxylation at the C6-, C8-, or C3′-position or the formation of the isoflavanes (9) and/or the biphenyl-ketone derivatives (10′) by metabolism or biotransformation.

  合成了四十八种异黄酮（8）、三十一种异黄烷（9）以及四十七种联苯酮（10, 10′），这些化合物是由十一种取代酚（11）和六种苯乙酸（12）合成的。其中，有七十五种化合物是新发现的。这些化合物的自由基清除活性在pH 6.0下使用1,1-二苯基-2-吡唑啉酮（DPPH）进行了评估。我们发现，在四十三种含有儿茶酚基的化合物中，三十九种在A环或B环上表现出与儿茶素相似的高活性（ED50=12—54 μM）。在这些情况下，它们结构的其他部分似乎对活性影响不大。许多6-或8-羟基异黄烷（9E—I）及其联苯酮衍生物（10E—H）也显示出高活性（ED50=<50 μM），而它们对应的异黄酮（8E—I）则完全没有活性。具有在C5位增加羟基（9D）或在C6位增加甲氧基（9J）的7-羟基异黄烷则展现出高活性（ED50=26—32 μM）。本研究表明，天然异黄酮通过在C6、C8或C3′位置的羟基化，或通过代谢或生物转化形成异黄烷（9）和/或联苯酮衍生物（10′），具有表现抗氧化活性的可能性。
• Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias
  申请人：——

  公开号：US20040235905A1

  公开（公告）日：2004-11-25

  Therapeutically active compounds of formula (I): wherein X is —O—, —CH 2 — or —C(O)—; Z is —CHR 9 — or valence bond; Y is —CH 2 —, —C(O)—, CH(OR 10 )—, —CH(NR 11 R 12 )—, —O—, —S—, —S(O)— or —S(O 2 )—, provided that in case Z is a valence bond, Y is not C(O); the dashed line represents an optional double bond in which case Z is —CR 9 — and Y is —CH—, C(OR 10 )— or —C(NR 11 R 12 )—; R 1 is —(CH 2 ) n NR 4 R 7 or one of the following groups: n is 1-4; R 2 and R 3 are independently H, lower alkyl, lower alkoxy, —NO 2 , halogen, —CF 3 , —OH, —NHR 8 or —COOH, R 4 and R 7 are independently H, lower alkyl or lower hydroxyalkyl; R 5 is H, lower alkoxy, —CF 3 , —NH 2 or —CN; R 6 is —NO 2 , —NR 14 R 19 , —CF 3 or R 8 and R 16 are independently H or acyl; R 9 is H or lower alkyl; R 10 is H, alkylsulfonyl or acyl; R 11 and R 12 are independently H, lower alkyl or acyl; R 13 and R 18 are independently H or —OR 20 ; R 14 and R 19 are independently H, acyl, alkylsulfonyl, C(S)NHR 17 or C(O)NHR 17 ; R 15 is H or NH 2 ; R 17 is H or lower alkyl; R 20 is H or acyl; and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds are potent inhibitors of Na + /Ca 2+ exchange mechanism. 1

  公式（I）中的治疗活性化合物：其中X是—O—，—CH2—或—C（O）—; Z是—CHR9—或价键; Y是—CH2—，—C（O）—，CH（OR10）—，—CH（NR11R12）—，—O—，—S—，—S（O）—或—S（O2）—，前提是如果Z是价键，则Y不是C（O）; 虚线表示可选的双键，在这种情况下Z是—CR9—，Y是—CH—，C（OR10）—或—C（NR11R12）—; R1是—（CH2）nNR4R7或以下组之一：n为1-4; R2和R3独立地为H，较低的烷基，较低的烷氧基，—NO2，卤素，—CF3，—OH，—NHR8或—COOH，R4和R7独立地为H，较低的烷基或较低的羟基烷基; R5为H，较低的烷氧基，—CF3，—NH2或—CN; R6为—NO2，—NR14R19，—CF3或R8和R16独立地为H或酰基; R9为H或较低的烷基; R10为H，烷基磺酰基或酰基; R11和R12独立地为H，较低的烷基或酰基; R13和R18独立地为H或—OR20; R14和R19独立地为H，酰基，烷基磺酰基，C（S）NHR17或C（O）NHR17; R15为H或NH2; R17为H或较低的烷基; R20为H或酰基; 其药学上可接受的盐和酯被披露。这些化合物是钠/钙交换机制的有效抑制剂。